Mylan N.V. reports that the United States Court of Appeals for the Federal Circuit upheld the validity and infringement of all four patents asserted by Mylan Specialty, L.P. protecting its respiratory drug, Perforomist (formoterol fumarate) inhalation solution. The court summarily affirmed the previous decision by the district court against Teva, according to a statement by Mylan.

The decision prevents Teva from receiving final approval of its abbreviated new drug application from the US Food and Drug Administration (FDA) prior to expiration of US Patent Nos. 6,667,344; 6,814,953; 7,348,362; and 7,462,645. Those patents cover Perforomist until they expire in June 2021.

Source: Mylan